Abstract 376P
Background
The clinical application of rapidly developing new molecular tests in breast cancer is debatable and often not affordable for most of the patients from developing countries. We assessed the adoption of molecular testing and their utility in breast cancer patients in the setting of a developing Nation.
Methods
We analysed the results of next-generation sequencing (NGS) based BRCA1 and 2 and multi-gene testing, immunohistochemistry based (IHC) based mismatch repair genes (MMR), Programmed cell death ligand 1(PDL1) and Androgen receptor (AR) testing done in breast cancer patients diagnosed from 2015 to 2018.
Results
There was an overall increase in the number of molecular tests offered to breast cancer patients in subsequent years. 141 patients opted for BRCA testing out of which 56 (40%) were triple negative (TNBC). 27(19%) out of 141 patients were BRCA mutated and 8(6%) had variants of unknown significance (VUS). Among 15 metastatic breast cancer patients tested for mutations on Multi-gene NGS, 3 had Her2neu amplification. Out of 8 TNBC cases, 5 had TP53 mutation, 1 had exon 14 skipping mutation of MET gene and 1 showed EGFR amplification. None of the five and six breast cancer patients with TNBC tested for MMR and PD-L1 were MMR deficient or positive respectively. Of the 7 TNBC patients tested, 4 were found to have Androgen receptor expression.
Conclusions
There is a significant rise in the use of modern molecular techniques in developing nations like India. However, Country Specific guidelines guided by International guidelines and awareness in patients with specific counseling on advantages and disadvantages of these tests may help in the usage of these techniques by most needy patients, breast cancer in particular.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rajiv Gandhi Cancer Institute and Research Centre, New Delhi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
YO20 - Can "Superman" have Chronic Myelomonocytic Leukemia?
Presenter: Alexander Luchinin
Session: Poster display session
Resources:
Abstract
YO21 - Sanctuary Site Central Nervous System Relapse-Refractory DLBCL Responding to Nivolumab and Lenalidomide.
Presenter: Irappa Madabhavi
Session: Poster display session
Resources:
Abstract
YO22 - External Auditory Canal Mass: A Case Series of Squamous Cell Carcinoma
Presenter: Mel Valerie Cruz-Ordinario
Session: Poster display session
Resources:
Abstract
YO23 - Soft tissue Giant cell tumor presented as Nasopharyngeal mass: A case report
Presenter: Emmelyn Buenacosa-Nepucpan
Session: Poster display session
Resources:
Abstract
YO25 - Hyperprogression after pembrolizumab in recurrent oropharyngeal cancer and the use of nab-paclitaxel as salvage treatment- A case report.
Presenter: Izzati Rosli
Session: Poster display session
Resources:
Abstract
YO26 - Exacerbation of radiation necrosis around the radiotherapy-pretreated brain metastases site after immune checkpoint inhibitors.
Presenter: Minako Nishio
Session: Poster display session
Resources:
Abstract
YO27 - Comparative Study Of 20Gray/5Fraction And 30Gray/10 Fraction Whole Brain Radiation In Brain Metastasis
Presenter: Pradip Bhandari
Session: Poster display session
Resources:
Abstract
YO28P - The response to anaplastic lymphoma kinase (ALK) inhibitor in metastatic anaplastic thyroid carcinoma (ATC)
Presenter: Nur Faizah Ab Muin
Session: Poster display session
Resources:
Abstract
YO29 - Acute kidney injury secondary to bilateral renal artery tumor thrombosis in a case of posterior mediastinal undifferentiated sarcoma: case report
Presenter: Ritsu Ibusuki
Session: Poster display session
Resources:
Abstract
YO30 - Follicular dendritic cell sarcoma of the tonsil- a multimodality approach
Presenter: Rich Ericson King
Session: Poster display session
Resources:
Abstract